{"filings":[{"id":114429,"accession_number":"0001628280-26-021941","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Champions Oncology appoints Dr. Brian Alexander to board, replacing Dr. Philip Breitfeld","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board accepted resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander effective March 24, 2026.","Dr. Alexander is CEO of Valo Health and CEO-Partner at Flagship Pioneering; formerly CEO of Foundation Medicine.","Appointment supports Champions' strategy to integrate patient-derived tumor models with molecular data for AI-driven R&D.","Dr. Breitfeld's resignation was not due to any disagreement with the company's operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114428,"accession_number":"0001628280-26-017259","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q3: study service rev record $16.6M (+32%); net loss $279k vs prior yr profit $4.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.","GAAP net loss of $279k (incl $423k stock comp, $341k D&A) vs net income $4.5M prior year.","Adjusted EBITDA $574k, down from $5.1M prior year; cost margins compressed by outsourced radiolabeling.","Ended quarter with $7.1M cash, no debt; management reaffirms full-year positive adj. EBITDA and revenue growth.","R&D expense $2.3M, up 32% for data platform and Corellia investments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":45590000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130806,"accession_number":"0001628280-25-057020","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.","Net income $237K; adjusted EBITDA $843K; prior-year net income $728K, adj. EBITDA $1.1M.","Year-to-date revenue $29.0M (+5%); net loss $230K; adj. EBITDA $962K vs $3.2M prior.","Cash $8.5M, no debt; management on track for full-year revenue growth and positive adj. EBITDA.","R&D spend up 55% YoY, G&A up 57% on investments in data platform and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":29030000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130805,"accession_number":"0001628280-25-045241","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Champions Oncology stockholders elect all seven director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; top vote-getter Scott R. Tobin with 9,722,734 votes for.","EisnerAmper LLP ratified as independent auditor for FY ending April 30, 2026 (10,659,115 for, 729 against).","Non-binding advisory resolution on executive compensation passed with 9,720,681 votes for, 7,262 against.","Broker non-votes of 931,779 were recorded on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147376,"accession_number":"0000771856-25-000022","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q1 FY2026 revenue $14.0M; adjusted EBITDA $60K vs $2.0M; CEO Rob Brainin appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.0M, down from $14.1M YoY; operating loss of $527K vs income of $1.3M.","Adjusted EBITDA fell to $60K from $2.0M; gross margin 43% vs 50%.","Rob Brainin appointed CEO; previously CEO? He signs report as CEO as of Sept 15, 2025.","Cash on hand $10.3M with no debt; net cash from operations $600K."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":13995000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147375,"accession_number":"0001628280-25-035727","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports record annual revenue $57M (+14%), net income $4.6M for FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record annual revenue $57M, up 14% YoY; net income $4.6M vs loss of $7.4M prior year.","Adjusted EBITDA income $7.1M (vs loss of $3.9M); year-end cash $9.8M with no debt.","Q4 revenue $12.3M, down 12% YoY; Q4 adjusted EBITDA loss of $1.2M.","Data license revenue contributed $4.7M for fiscal year; new high-margin data business launched.","CEO cites return to growth and profitability; strong pipeline for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147374,"accession_number":"0001628280-25-035424","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Champions Oncology appoints Robert Brainin as CEO effective Aug 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Brainin named CEO, effective August 25, 2025; he was a Board member since Feb 2021.","Annual base salary of $500,000; target incentive bonus of 75% of base salary.","Equity awards: 225,000 options (4-year vest) and 475,000 performance-based options.","Ronnie Morris, M.D., transitions to Executive Chairman; Joel Ackerman becomes Director.","Brainin brings 25+ years life sciences/tech experience; most recently CBO at Veracyte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183542,"accession_number":"0001628280-25-012022","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports record Q3 revenue $17.0M, net income $4.5M, first data licensing deal up to $8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue up 42% YoY to $17.0M; net income of $4.5M vs loss of $2.6M in prior year quarter.","Adjusted EBITDA $5.2M; gross margin improved to 61% from prior 35% on cost reductions.","Signed first major data licensing agreement worth up to $8.0M; hired Matt Newman as EVP/GM for data platform.","Year-to-date revenue $44.6M (+23% YoY); net income $6.5M vs loss of $7.1M in prior nine months.","No debt; cash $3.2M; expects quarterly revenue fluctuations but positioned for sustained profitability."],"consensus_eps_estimate":-0.0102,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":44589000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200119,"accession_number":"0001628280-24-050789","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q2 FY2025: Revenue $13.5M, Net Income $730K, Adj. EBITDA $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue rose 17% YoY to $13.5M; gross margin improved to 45% from 43%","Net income of ~$730K vs. $2.0M operating loss a year ago","Adjusted EBITDA of $1.1M, reversed from a $1.4M loss in Q2 FY2024","Company guides FY2025 revenue growth of at least 10%-15%, citing core strength and new data platform revenue","No debt; cash on hand ~$2.8M; data monetization highlighted as a transformative additional revenue stream"],"consensus_eps_estimate":-0.204,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":27550000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200118,"accession_number":"0001628280-24-042780","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Champions Oncology stockholders elect directors, ratify auditor, approve advisory compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected with majority votes; Ronnie Morris, M.D. received 8,483,091 for and 685,123 withheld.","Ratification of EisnerAmper LLP as auditor for FY ending April 30, 2025 passed with 9,865,571 votes for, 256 against.","Non-binding advisory resolution on named executive officer compensation approved with 9,162,287 for, 2,027 against.","Broker non-votes of 697,813 were recorded on director elections and the compensation proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200117,"accession_number":"0001628280-24-042039","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Champions Oncology President Brady Davis passes away unexpectedly","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President Brady Davis passed away unexpectedly in the week ending October 3, 2024.","Davis had served as President since October 2023.","No successor has been announced; CEO Ronnie Morris continues in his role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216137,"accession_number":"0001628280-24-040137","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q1 revenue $14.1M, net income $1.3M, adjusted EBITDA $2.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue rose 12% YoY to $14.1M; net income of $1.3M vs. loss of $2.6M a year ago.","Adjusted EBITDA of $2.0M vs. loss of $1.7M; margin improved to 49.7% from 38.8%.","Total costs and expenses fell 15.8% to $12.7M; cash $2.9M with zero debt.","CEO cites cost cuts and leaner operations; expects some volatility but sustained EBITDA profitability.","Conference call scheduled for Sept. 11 at 4:30 p.m. EDT."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":14061000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216136,"accession_number":"0001628280-24-032227","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.","FY2024 revenue $50.2M (-7% YoY); FY adjusted EBITDA loss $3.9M vs loss $1.3M prior year.","Q4 gross margin 48% (pharmacology services 49%); FY gross margin 41% vs 45% prior year.","Cash $2.6M, no debt; stock repurchase program paused; Corellia AI unit seeking external capital.","Q4 operating loss $190K narrowed from $2.5M prior year; cost-cutting measures improving bottom line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253424,"accession_number":"0001628280-24-010569","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q3 revenue down 6% to $12.0M; operating loss widens to $2.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 FY2024 revenue $12.0M, down from $12.8M YoY; gross margin fell to 34.7% from 39.7%.","Operating loss of $2.6M vs $2.5M a year ago; adjusted EBITDA loss of $1.7M.","Nine-month revenue $36.2M, down 11.4%; operating loss of $7.1M vs $2.7M loss YoY.","Cash and equivalents $4.5M at quarter end; no debt outstanding.","Company seeking capital for Corellia AI subsidiary; two lead targets progress toward licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":36153000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270890,"accession_number":"0001628280-23-041308","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.","Gross margin fell to 42.8% from 47.9% on lower revenue and fixed costs.","FY2024 revenue guidance revised to be generally flat YoY, citing customer cancellations.","Hired Brady Davis as President to lead new strategic initiatives.","Corellia AI drug discovery advancing with two lead targets; seeking capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":24134000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270889,"accession_number":"0001628280-23-034703","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Champions Oncology annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; Scott Tobin and Philip Breitfeld each received over 9.6M votes for.","Ratification of EisnerAmper as independent auditor for FY ending April 30, 2024 passed with 10,041,893 votes for.","Non-binding advisory vote on executive compensation approved with 9,444,385 votes for (257,887 abstentions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270888,"accession_number":"0001628280-23-034475","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Champions Oncology appoints Brady Davis as President, effective Oct 9, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brady Davis appointed President; annual base salary of $425,000 plus 50% target bonus.","Davis receives 135,000 stock options vesting over 4 years and 7,500 vesting over 1 year.","Davis brings 25+ years experience from Illumina, Oracle, Hewlett Packard, DNAnexus, and Canexia Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287799,"accession_number":"0001628280-23-032185","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.","Operating loss $2.6M vs loss of $284K; adjusted EBITDA loss $1.7M vs positive $450K.","Cash $5.0M, no debt; net cash used in ops $4.0M for the quarter.","CEO cites biotech downturn; bookings improving, expects revenue growth in H2.","Drug discovery subsidiary Corellia AI progressing; company seeking capital to accelerate programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":12561000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287798,"accession_number":"0001628280-23-025452","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports Q4 revenue $13.1M (+2% YoY); full-year record $53.9M but operating loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.","Full-year operating loss $5.3M vs income $607M; adjusted EBITDA loss $1.3M vs +$3.1M.","Gross margin fell to 44% (Q4) and 45% (FY) from 52% in prior-year periods due to study cancellations.","Cash $10.1M, no debt; CFO projects return to profitability in H2 of current fiscal year.","Announced formation of wholly owned biotech subsidiary Corellia AI for therapeutic drug discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308108,"accession_number":"0001628280-23-010813","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Champions Oncology announces $5M share repurchase program through April 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $5M of common stock repurchases through April 30, 2024.","Purchases will be made in open market transactions under Rule 10b-18.","CEO Ronnie Morris cites confidence in strategic priorities and long-term prospects.","CFO David Miller notes balance sheet strength and current valuation as buying opportunity.","Program may be suspended, modified, or terminated at any time without notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326997,"accession_number":"0001628280-23-008080","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.","Operating loss of $2.5M vs income of $0.83M in prior year; adjusted EBITDA loss of $1.6M vs positive $1.5M.","Record quarterly bookings; cash on hand $11.6M with no debt; net cash from ops $1.6M in Q3.","R&D spend increased $1.0M (46.8%) to $3.2M, mainly for therapeutic target discovery platform.","CEO expects improved results in fiscal 2024; YTD revenue up 12.6% to $40.8M but operating loss of $2.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":40799000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344720,"accession_number":"0001628280-22-031796","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports record Q2 revenue of $14.3M, cuts FY growth outlook to 10-15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $14.3M, up 21% YoY from $11.8M.","Adjusted EBITDA of $686K, down from $743K in prior-year period.","Operating income just $7K; gross margin fell to 48% from 52%.","Full-year growth target revised to 10%-15% due to increased cancellations and economic slowdown.","Cash on hand $10.8M, no debt; cash from operations $3.3M for the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":28026000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344719,"accession_number":"0001628280-22-026738","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Champions Oncology stockholders elect all seven director nominees at 2022 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven directors elected: Ronnie Morris, Joel Ackerman, David Sidransky, Daniel Mendelson, Robert Brainin, Scott Tobin, Philip Breitfeld.","Ratification of EisnerAmper LLP as independent auditor for FY2023 passed with 9,231,979 votes for.","Non-binding advisory vote on named executive officer compensation approved with 9,025,636 votes for.","All proposals passed with strong majority; no broker non-votes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361194,"accession_number":"0001628280-22-024587","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.","Adjusted EBITDA $450K vs $422K; operating loss $284K includes $206K stock comp and $528K D&A.","Gross margin 49% vs 52% due to higher study expenses and SaaS costs; bookings at record level.","Cash $8.1M, no debt; net cash used in ops $195K, investing $754K for lab equipment.","Alloy Therapeutics partnership delivered series of antibody hits."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":13745000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361193,"accession_number":"0001628280-22-019249","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.","FY2022 gross margin improved to 52% (from 48%); adjusted EBITDA $3.1M vs $2.1M.","Operating income $607K for FY2022; cash $9.0M, no debt.","Guidance: projects another year of top-line growth of ~20% for FY2023.","CEO notes expanding ex-vivo services and computational discovery tools moving to preclinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398521,"accession_number":"0001628280-22-006255","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.","Adjusted EBITDA was $1.5M; net income from operations of $830K (incl. $310K stock comp).","Gross margin for Q3 was 51.4% vs 57.2% a year ago; nine-month gross margin improved to 51.9% from 48.8%.","Cash position $8.7M with no debt; signed co-development partnerships with Fannin Innovation Studio and Gigamune.","Company reaffirms FY2022 revenue growth guidance of 15%-20%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":36232000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417527,"accession_number":"0001628280-21-024928","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2021-12-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports record Q2 revenue $11.8M, up 17% YoY; operating income $263K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $11.8M, up 17% from $10.1M year ago.","GAAP operating income of $263K vs. $7K a year ago; non-GAAP operating income $743K vs. $399K.","Gross margin improved to 52.4% from 44.2% due to reduced outsourcing.","Cash position $4.8M, no debt; net cash from ops $1.2M in quarter.","R&D investment increased 39.3% to $2.3M for therapeutic target discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":23039000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417526,"accession_number":"0001628280-21-020321","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2021-10-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Champions Oncology annual meeting results: all proposals approved by shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; Scott R. Tobin received highest support (8,518,378 votes).","EisnerAmper LLP ratified as independent auditor for FY2022 (8,762,596 for, 326 against).","Non-binding advisory vote on named executive officer compensation passed (8,531,715 for, 103,135 against).","2021 Equity Incentive Plan approved by stockholders (7,451,194 for, 1,211,189 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435093,"accession_number":"0001628280-21-018477","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology Q1 revenue record $11.3M, up 18% YoY; non-GAAP op income $422k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue of $11.3M, +17.9% YoY, driven by larger studies and platform expansion.","GAAP operating loss of $175k; non-GAAP operating income of $422k, excluding $280k stock comp and $317k D&A.","Gross margin improved to 52.0% from 44.1% as more lab work was performed internally.","Cash position $4.0M with no debt; net cash from operations $216k in the quarter.","Validated 6 therapeutic discovery targets; SaaS platform Lumin Bioinformatics adding new users."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":11253000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435092,"accession_number":"0001628280-21-014235","cik":771856,"company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","form_type":"8-K","filed_at":"2021-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Champions Oncology reports record FY2021 revenue of $41M (+28% YoY); turns to operating profit of $338K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $41.0M, up 28% from $32.1M; Q4 revenue $10.6M, up 21% from $8.8M.","Full-year operating income of $338K vs loss of $1.9M; Q4 operating loss narrowed to $456K from $2.0M.","Gross margin improved to 48% (FY2021) and 47% (Q4) vs 47% and 43% a year ago.","Cash position $4.7M with no debt; net cash used in ops $1.7M for the year.","Launched Lumin SaaS platform; developing AI/ML-driven target discovery using proprietary datasets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":81515673.90643273,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}